발기부전 치료제 시장 예측(-2030년) : 세계 분석 - 약제 유형별, 투여 경로별, 유통 채널별, 지역별

According to Stratistics MRC, the Global Erectile Dysfunction Drugs Market is accounted for $2.83 billion in 2023 and is expected to reach $5.11 billion by 2030 growing at a CAGR of 8.8% during the forecast period. Erectile dysfunction (ED) drugs are medications designed to treat the inability to achieve or maintain an erection sufficient for sexual intercourse. They work by increasing blood flow to the penis, facilitating an erection when sexually stimulated. Common ED drugs include sildenafil (Viagra), tadalafil (Cialis), and vardenafil (Levitra), which belong to a class of medications called phosphodiesterase type 5 (PDE5) inhibitors. These drugs are typically taken orally and have revolutionized the treatment of ED, offering millions of men a reliable and effective solution to enhance their sexual performance and quality of life.

According to the Clinical Epidemiology and Global Health Journal, Erectile Dysfunction affects more than 150 million men globally, and by 2025, that number is predicted to rise to 322 million. According to the National Institutes of Health (NIH), in 2022, erectile dysfunction (ED) is very common condition in U.S. It affects about 30 million men in the U.S. every year.

Market Dynamics:

Driver:

Growing awareness and acceptance

The growing awareness and acceptance of ED drugs in the erectile dysfunction market signifies the increasing recognition and normalization of ED as a medical condition. As societal attitudes evolve and conversations around sexual health become more open, individuals are more likely to seek treatment for ED. This shift in perception leads to greater acceptance of ED drugs as legitimate solutions, boosting their demand. Additionally, education campaigns and advertising efforts play a crucial role in spreading awareness about available treatment options, further fueling market growth.

Restraint:

Regulatory hurdles

Regulatory hurdles in the erectile dysfunction drug market primarily stem from stringent approval processes and ongoing monitoring by health authorities. These hurdles include rigorous clinical trials to establish safety and efficacy, as well as compliance with labeling and advertising regulations. Additionally, concerns over potential side effects and interactions with other medications contribute to the regulatory complexity. Market entry may also be delayed by patent protections and intellectual property disputes. Navigating these regulatory hurdles demands substantial resources and expertise, which can restrain competition and innovation in the ED drug market.

Opportunity:

Innovation in drug development

The innovation in drug development within the erectile dysfunction market presents a promising opportunity for both pharmaceutical companies and patients. With advancements in understanding the underlying causes of ED, such as vascular issues, neurological disorders, and hormonal imbalances, researchers can target novel pathways for drug interventions. This innovation could lead to more effective and safer treatment options, potentially with fewer side effects compared to current medications like Viagra and Cialis. Furthermore, breakthroughs in personalized medicine may enable tailored treatments based on individual patient characteristics, enhancing efficacy and patient satisfaction.

Threat:

Patent expiry

The patent expiry threat in the Erectile Dysfunction drugs market refers to the looming loss of exclusivity for major medications like Viagra, Cialis, and Levitra. As these patents expire, generic versions can enter the market, leading to intense competition and price erosion for the original brands. This could significantly impact revenue streams for pharmaceutical companies that have held exclusive rights to these drugs. Moreover, generic alternatives often come at lower prices, enticing consumers away from branded products. This scenario poses a challenge for companies to maintain market share and profitability in the face of increased competition.

Covid-19 Impact:

The COVID-19 pandemic had a significant impact on the erectile dysfunction (ED) drug market. With restrictions on movement and healthcare priorities shifting towards managing the pandemic, the demand for ED drugs saw fluctuations. While initial lockdowns led to a decrease in doctor visits and prescriptions, there was a subsequent rise in demand as restrictions eased and telemedicine became more prevalent. Due to house restrictions, there was a substantial growth of intimate activities among newlywed couples and others, which consequently led to growth of several things related to intercourse including ED drugs. Economic uncertainties also influenced consumer spending on non-essential medications like ED drugs.

The viagra (sildenafil citrate) segment is expected to be the largest during the forecast period

The growth of the Viagra (Sildenafil Citrate) segment in the ED drug market can be attributed to several factors. Viagra was one of the pioneering drugs in ED treatment, establishing a strong brand presence and trust among consumers. Its efficacy in treating ED is well-established, leading to widespread adoption by physicians and patients alike. The availability of generic versions of Sildenafil Citrate has increased affordability and accessibility, further fueling market growth. Moreover, continuous research and development efforts have resulted in innovative formulations and delivery methods, expanding the market reach. Furthermore, increasing awareness about ED and the destigmatization of seeking treatment have contributed to the overall expansion of the ED drug market, with Viagra leading the charge.

The topical medications segment is expected to have the highest CAGR during the forecast period

The growth in the topical medication segment can be attributed to the convenience and discretion offered by topical formulations, appealing to consumers seeking non-invasive treatment options. Advancements in formulation technology have improved the efficacy and absorption rates of topical medications, enhancing their effectiveness. The growing awareness and acceptance of topical treatments among both patients and healthcare providers have fuelled market demand. Additionally, the preference for localized treatment with fewer systemic side effects has bolstered the adoption of topical medications, contributing to the segment's sustained expansion.

Region with largest share:

The North American region has experienced significant growth in the erectile dysfunction drug market due to increasing awareness about ED and its growing treatment options. Advancements in medical technology have led to the development of more effective and safer ED drugs, boosting consumer confidence and uptake. Additionally, the aging population in North America, coupled with lifestyle factors such as stress and sedentary habits, has contributed to the rise in ED cases, thus driving the demand for treatment. Robust healthcare infrastructure and favourable reimbursement policies in the region have facilitated access to ED drugs, further fuelling market growth.

Region with highest CAGR:

The Asia-Pacific region has witnessed a notable surge due to several factors. Increasing awareness about sexual health, the rising incidence of lifestyle-related disorders, and expanding access to healthcare services are key drivers. Furthermore, cultural shifts towards more open discussions about sexual health have reduced stigma, encouraging individuals to seek treatment. Furthermore, the availability of innovative treatment options has fuelled market growth. With a large population base and improving healthcare infrastructure, the Asia-Pacific region presents significant opportunities for further expansion in the erectile dysfunction drug market.

Key players in the market

Some of the key players in Erectile Dysfunction Drugs market include Abbott Laboratories, Allergan plc, Apricus Biosciences, Inc., Bayer AG, Cristalia Produtos Quimicos Farmaceuticos Ltda., Dong-A Pharmaceutical Co., Ltd., Eli Lilly and Company, Endo International plc, Futura Medical plc, Ion Channel Innovations, LLC, Johnson & Johnson, Meda Pharmaceuticals Inc., Metuchen Pharmaceuticals, LLC, Pfizer Inc., Regent Pacific Group Limited, Sandoz International GmbH, Sinil Pharmaceutical Co., Ltd., SK Chemicals Co., Ltd., Teva Pharmaceutical Industries Ltd. and VIVUS, Inc.

Key Developments:

In March 2024, Johnson & Johnson's JNJ wholly-owned subsidiary, Johnson & Johnson MedTech, recently announced its partnership with Nvidia to accelerate secure, real-time analysis of surgical data using artificial intelligence (AI). The two businesses collaborated to enable more global availability of AI algorithms and real-time analytical access. Their goal is to have an impact on surgical decision-making, teamwork, and education in all linked operating rooms (ORs).

In January 2024, Glenmark said it has partnered with Pfizer to launch abrocitinib in India used for treatment of moderate-to-severe atopic dermatitis (AD). Glenmark and Pfizer will co-market abrocitinib in India under the brand names JABRYUS and CIBINQO. Developed by Pfizer, abrocitinib has received marketing authorization for abrocitinib in adults with moderate-to-severe atopic dermatitis from the Central Drugs Standard Control Organization (CDSCO).

Drug Types Covered:

• Viagra (Sildenafil Citrate)
• Avanafil (Stendra/Spedra)
• Cialis (Tadalafil)
• Helleva (Lodenafil Carbonate)
• Levitra/Staxyn (Vardenafil)
• Mvix (Mirodenafil)
• Vitaros (Alprostadil)
• Zydena (Udenafil)
• Other Drug Types

Route of Administrations Covered:

• Oral Medications
• Topical Medications
• Injections

Distribution Channels Covered:

• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Emerging Markets
• 3.7 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Erectile Dysfunction Drugs Market, By Drug Type

• 5.1 Introduction
• 5.2 Viagra (Sildenafil Citrate)
• 5.3 Avanafil (Stendra/Spedra)
• 5.4 Cialis (Tadalafil)
• 5.5 Helleva (Lodenafil Carbonate)
• 5.6 Levitra/Staxyn (Vardenafil)
• 5.7 Mvix (Mirodenafil)
• 5.8 Vitaros (Alprostadil)
• 5.9 Zydena (Udenafil)
• 5.10 Other Drug Types

6 Global Erectile Dysfunction Drugs Market, By Route of Administration

• 6.1 Introduction
• 6.2 Oral Medications
• 6.3 Topical Medications
• 6.4 Injections

7 Global Erectile Dysfunction Drugs Market, By Distribution Channel

• 7.1 Introduction
• 7.2 Hospital Pharmacies
• 7.3 Online Pharmacies
• 7.4 Retail Pharmacies

8 Global Erectile Dysfunction Drugs Market, By Geography

• 8.1 Introduction
• 8.2 North America
  • 8.2.1 US
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 Italy
  • 8.3.4 France
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 New Zealand
  • 8.4.6 South Korea
  • 8.4.7 Rest of Asia Pacific
• 8.5 South America
  • 8.5.1 Argentina
  • 8.5.2 Brazil
  • 8.5.3 Chile
  • 8.5.4 Rest of South America
• 8.6 Middle East & Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 UAE
  • 8.6.3 Qatar
  • 8.6.4 South Africa
  • 8.6.5 Rest of Middle East & Africa

9 Key Developments

• 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 9.2 Acquisitions & Mergers
• 9.3 New Product Launch
• 9.4 Expansions
• 9.5 Other Key Strategies

10 Company Profiling

• 10.1 Abbott Laboratories
• 10.2 Allergan plc
• 10.3 Apricus Biosciences, Inc.
• 10.4 Bayer AG
• 10.5 Cristalia Produtos Quimicos Farmaceuticos Ltda.
• 10.6 Dong-A Pharmaceutical Co., Ltd.
• 10.7 Eli Lilly and Company
• 10.8 Endo International plc
• 10.9 Futura Medical plc
• 10.10 Ion Channel Innovations, LLC
• 10.11 Johnson & Johnson
• 10.12 Meda Pharmaceuticals Inc.
• 10.13 Metuchen Pharmaceuticals, LLC
• 10.14 Pfizer Inc.
• 10.15 Regent Pacific Group Limited
• 10.16 Sandoz International GmbH
• 10.17 Sinil Pharmaceutical Co., Ltd.
• 10.18 SK Chemicals Co., Ltd.
• 10.19 Teva Pharmaceutical Industries Ltd.
• 10.20 VIVUS, Inc.